YOU ARE HERE:
Treatment interruptions news
page  of 3
 
Headline
Date
  Thrombocytopenia associated with treatment interruptions: HIV replication a cause
12.01.10
  ‘Drug holidays’ best predictor of treatment failure, adherence studies find
23.11.09
  Early treatment and interruption makes no difference to disease progression, study finds
04.09.09
  Study finds smaller CD4 response to successful antiretroviral therapy following treatment interruptions
29.12.08
  If you can't switch, better to stay on failing treatment than stop it, studies show
14.11.08
  Treatment breaks set for a come-back?
12.11.08
  Continued antiretroviral therapy reduces bone mineral density in SMART study
27.10.08
  BHIVA: Many patients and clinicians still need educating about the benefits of treatment
08.05.08
  Planned interruption of highly active antiretroviral therapy does not select drug resistance mutations in HIV-1-infected children
07.05.08
  Os benefícios de um início mais precoce do tratamento ARV superam o risco de toxicidades, revela o estudo SMART
28.04.08
  Benefit of starting HIV treatment early outweighs the risk of toxicities, SMART study shows
14.04.08
  SMART study reaffirms that HIV replication is harmful, even at CD4 counts above 350
14.04.08
  CROI: Biomarker changes may help explain detrimental effects of treatment interruption
07.02.08
  CROI: Risk of treatment interruption persists after restarting HAART
05.02.08
  High prevalence of asymptomatic heart disease in HIV-positive patients
09.01.08
  Up to 40% of ART recipients in Africa have died or discontinued treatment within two years
17.10.07
  ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance
19.09.07
  IAS: ART interruption particularly unsafe for HIV-positive patients coinfected with hepatitis B or C
24.07.07
  Roche agrees to temporary suspension of nelfinavir's (Viracept) European license - updated
21.06.07
  Near-global nelfinavir (Viracept) recall 'very difficult situation'
20.06.07

page  of 3